Therefore, a consequence of AR-targeted therapy-induced hypoxia may be to increase CXCR2 expression in tumor cells, which by extension results in the selection of cells undergoing transition to neuroendocrine prostate cancer, a known driver of castration-resistance. The gene discussed is AR; the disease is neoplasm.